

# Paola Matteucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7965481/publications.pdf>

Version: 2024-02-01

35  
papers

4,125  
citations

361296

20  
h-index

395590

33  
g-index

35  
all docs

35  
docs citations

35  
times ranked

5486  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. <i>Blood</i> , 2002, 99, 3838-3843.   | 0.6 | 2,907     |
| 2  | Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.  | 0.6 | 201       |
| 3  | Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007, 21, 2316-2323. | 3.3 | 142       |
| 4  | Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.  | 0.6 | 99        |
| 5  | High-Dose Yttrium-90â€“Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.   | 0.8 | 68        |
| 6  | Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. <i>Blood</i> , 2002, 100, 1104-1105.   | 0.6 | 58        |
| 7  | Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1270-1276.  | 2.0 | 55        |
| 8  | High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. <i>Bone Marrow Transplantation</i> , 2002, 30, 725-732.                                | 1.3 | 47        |
| 9  | Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004, 103, 3287-3295.                                       | 0.6 | 47        |
| 10 | Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. <i>Transfusion</i> , 1999, 39, 48-55.  | 0.8 | 46        |
| 11 | Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. <i>British Journal of Cancer</i> , 2006, 94, 1016-1020.   | 2.9 | 39        |
| 12 | Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. <i>Gene Therapy</i> , 1998, 5, 465-472.  | 2.3 | 38        |
| 13 | Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. <i>Leukemia Research</i> , 2002, 26, 1131-1133.   | 0.4 | 36        |
| 14 | Phase <scp>II</scp> study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.  | 1.2 | 36        |
| 15 | High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004, 126, 815-820.   | 1.2 | 35        |
| 16 | Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 783-791.                 | 0.4 | 35        |
| 17 | Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1251-1259. | 0.6 | 34        |
| 18 | Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.   | 3.3 | 27        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.   | 1.3 | 25        |
| 20 | Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous $\text{I}\pm$ -interferon. <i>European Journal of Cancer</i> , 1994, 30, 1292-1298.  | 1.3 | 23        |
| 21 | Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. <i>Bone Marrow Transplantation</i> , 1999, 23, 323-327.   | 1.3 | 19        |
| 22 | High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.                          | 0.6 | 17        |
| 23 | Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose $\text{I}\pm$ Y-ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013, 31, 2974-2976. | 0.8 | 14        |
| 24 | Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.   | 0.5 | 14        |
| 25 | Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.  | 1.7 | 11        |
| 26 | Serum Levels of Soluble Cell Adhesion Molecules (ICAM-1, VCAM-1, E-Selectin) and of Cytokine $\text{TNF}\text{-I}\pm$ Increase during Interleukin-2 Therapy. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 142-147.  | 2.1 | 10        |
| 27 | Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014, 49, 485-491.  | 1.3 | 10        |
| 28 | Isolated Left Ventricular Filling Abnormalities May Predict Interleukin-2-Induced Cardiovascular Toxicity. <i>Journal of Immunotherapy</i> , 1996, 19, 134-141.   | 1.2 | 9         |
| 29 | Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. <i>Bone Marrow Transplantation</i> , 2010, 45, 1119-1120.  | 1.3 | 9         |
| 30 | Radioimmunotherapy and secondary leukemia: A case report. <i>Leukemia Research</i> , 2010, 34, e1-e4.   | 0.4 | 4         |
| 31 | Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.   |     | 4         |
| 32 | Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.  | 0.9 | 3         |
| 33 | Intraleural Administration of Interleukin-2 and Lak Cells in Locally Advanced Non-Small-Cell Lung Cancer. A Case Report. <i>Tumori</i> , 1994, 80, 246-250.   | 0.6 | 2         |
| 34 | Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.  | 0.6 | 1         |
| 35 | Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma. <i>American Journal of Blood Research</i> , 2012, 2, 105-12.                 | 0.6 | 0         |